Petter Olsson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 2022;10(12):3156-3162

Allergic Fungal Rhinosinusitis: The Role and Expectations of Biologics

Luong AU; Chua A; Alim BM; Olsson P; Javer A
Article: ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY. 2021;17(1):55

HealthSWEDE: costs with sublingual immunotherapy-a Swedish questionnaire study

Olsson P; Skroder C; Ahlbeck L; Hjalte F; Welin K-O; Westin U; Andersson M; Ahlstrom-Emanuelsson C; Cardell L-O
Article: RESPIRATORY RESEARCH. 2020;21(1):93

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study

Mackay AJ; Kostikas K; Roche N; Frent S-M; Olsson P; Pfister P; Gupta P; Patalano F; Banerji D; Wedzicha JA
Article: RESPIROLOGY. 2020;25(4):393-400

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naive COPD patients: A pooled analysis

Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Article: INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2019;14:995-1008

Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study

Larsson K; Janson C; Stallberg B; Lisspers K; Olsson P; Kostikas K; Gruenberger J-B; Gutzwiller FS; Uhde M; Jorgensen L; Johansson G
Article: RESPIROLOGY. 2018;23(12):1152-1159

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV
Article: RESPIRATORY RESEARCH. 2018;19(1):172

Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study

Janson C; Johansson G; Stallberg B; Lisspers K; Olsson P; Keininger DL; Uhde M; Gutzwiller FS; Jorgensen L; Larsson K
Article: INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2018;13:1125-1134

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
Article: RESPIRATORY RESEARCH. 2017;18(1):206

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Bjermer L; van Boven JFM; Costa-Scharplatz M; Keininger DL; Gutzwiller FS; Lisspers K; Mahon R; Olsson P; Roche N
Article: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2017;195(9):1189-1197

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment Data from the FLAME Trial

Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Journal article: PNEUMOLOGIE. 2017;71(S 01):s1-s125

Einmal täglich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal täglich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens einer Exazerbation im Vorjahr: die FLAME Studie

Vogelmeier C; Wedzicha J; Chapman K; Ayers T; FowlerTaylor A; Thach C; Olsson P; Shrinivasan A; Fogel R; Patalano F; Banerji D
Article: ACTA OTO-LARYNGOLOGICA. 2016;136(8):852-859

Treatment of idiopathic rhinitis with kinetic oscillations - a multi-centre randomized controlled study

Ehnhage A; Johnsson PS; Ahlstrom-Emanuelsson C; Andersson M; Knutsson J; Lien J; Norlander T; Olsson P; Friis-Liby J-E; Holmstrom M
Article: NPJ PRIMARY CARE RESPIRATORY MEDICINE. 2016;26:15082

TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study

Cardell L-O; Olsson P; Andersson M; Welin K-O; Svensson J; Tennvall GR; Hellgren J
Journal article: PNEUMOLOGIE. 2015;69(S 01)

QVA149 reduziert das Risiko moderater bis schwerer Exazerbationen im Vergleich zu unverblindetem Tiotropium bei Patienten mit schwerer COPD: Die SPARK-Studie

Ficker J; Wedzicha W; Decramer M; Olsson P; Chen H; Fogel R; Banerji D
Article: ACTA OTO-LARYNGOLOGICA. 2013;133(9):939-943

Effects of FESS and additional fluticasone propionate nasal drops on psychological well-being in nasal polyposis with asthma

Nordin S; Olsson P; Blomqvist EH; Stjarne P; Ehnhage A
Article: PRIMARY CARE RESPIRATORY JOURNAL. 2012;21(4):412-418

Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis

Svensson J; Lundberg J; Olsson P; Stjarne P; Tennvall GR
Article: PRIMARY CARE RESPIRATORY JOURNAL. 2012;21(2):174-179

High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care

Stjarne P; Odeback P; Stallberg B; Lundberg J; Olsson P
Article: ACTA OTO-LARYNGOLOGICA. 2011;131(8):826-832

Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma

Nordin S; Blomqvist EH; Olsson P; Stjarne P; Ehnhage A
Article: RHINOLOGY. 2010;48(3):325-330

Quality of life is improved by endoscopic surgery and fluticasone in nasal polyposis with asthma

Olsson P; Ehnhage A; Nordin S; Stjarne P
Journal article: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2010;143(S2):p130-p131

Improved Asthma and Olfaction Parameters One Year Post‐ESS

Stjarne P; Olsson P
Article: RHINOLOGY. 2010;48(2):150-155

Endoscopic Sinus Surgery improves olfaction in nasal polyposis, a multi-center study

Olsson P; Stjarne P
Article: ALLERGY. 2009;64(11):1663-1670

Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis

Holmberg K; Tonnel A-B; Dreyfus I; Olsson P; Cougnard J; Mesbah K; Devillier P
Article: ALLERGY. 2009;64(5):762-769

Functional endoscopic sinus surgery improved asthma symptoms as well as PEFR and olfaction in patients with nasal polyposis

Ehnhage A; Olsson P; Kolbeck K-G; Skedinger M; Dahlen B; Alenius M; Stjarne P
Article: RESPIRATORY MEDICINE. 2008;102(10):1406-1411

Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler

Zetterstrom O; Dahl R; Lindqvist A; Olsson P
Journal article: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2007;137(S2):p273

P188: Mometasone Furoate Prolongs Post‐FESS Return of Nasal Polyps

Stjärne P; Olsson P
Article: ACTA OTO-LARYNGOLOGICA. 2003;123(1):75-80

Prevalence of self-reported allergic and non-allergic rhinitis symptoms in Stockholm:: Relation to age, gender, olfactory sense and smoking

Olsson P; Berglind N; Bellander T; Stjärne P
Visa fler

Alla övriga publikationer

Preprint: AUTHOREA PREPRINTS. 2024

Omalizumab for the Treatment of Allergic Rhinitis: A Systematic Review and Meta-Analysis

Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
Review: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 2022;10(10):2570-2578

The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review

Taniguchi M; Heffler E; Olze H; White A; Corte-Real J; Olsson P; Lazarewicz S
Review: RHINOLOGY. 2021;59(6):501-510

Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis

Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
Preprint: RESEARCH SQUARE. 2020

Research HealthSWEDE: Costs With Sublingual Immunotherapy - A Swedish Questionnaire Study

Olsson P; Sköder C; Ahlbeck L; Hjalte F; Welin K-O; Westin U; Andersson M; Emanuelsson CA; Cardell L-O
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2019;54:pa2546

Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients

Nissen F; Humbert M; Gibson P; Kostikas K; Jaumont X; Olsson P; Alvares L; Bousquet J
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2018;52:pa4376

Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis

Muro S; Yoshisue H; Mackay AJ; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2018;52:pa4387

Baseline symptom burden and dual bronchodilator response in the FLAME study

Mackay A; Kostikas K; Frent S-M; Olsson P; Pfister P; Gupta P; Patalano F; Banerji D; Wedzicha JA
Letter: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2018;197(7):968-969

The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease Reply

Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Letter: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2017;196(9):1230-1231

What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Reply

Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa939

Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients

Bjermer L; van Boven JFM; Costa-Scharplatz M; Gutzwiller FS; Lisspers K; Mahon R; van der Molen T; Olsson P; Roche N; Burke C
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa936

Estimating the number of patients' needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study

Bjermer L; Roche N; Gutzwiller FS; Olsson P; Patalano F; Thach C; Fogel R; Banerji D
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa1802

Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study

Chapman K; Kostikas K; Olsson P; Thach C; Patalano F; Fogel R; Banerji D
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa1075

Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study

Wedzicha J; Vogelmeier CF; Ayers T; Olsson P; Patalano F; Thach C; Fogel R; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa989

Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study

Wedzicha J; Vogelmeier CF; Ayers T; FowlerTaylor A; Thach C; Olsson P; Fogel R; Patalano F; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa984

Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on hypothalamic pituitary-adrenal axis function in moderate-to-very severe COPD patients: Results from the FLAME study

Olsson P; Vogelmeier C; Chapman K; FowlerTaylor A; Ayers T; Thach C; Fogel R; Patalano F; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa3946

ICS and risk of pneumonia in Swedish COPD patients: The ARCTIC study

Janson C; Johansson G; Stallberg B; Lisspers K; Olsson P; Keininger D; Jorgensen L; Sobocki P; Larsson K
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa3933

Extent and impact of late vs early stage COPD diagnosis in the Swedish ARCTIC study

Larsson KA; Janson C; Stallberg B; Lisspers K; Olsson P; Kostikas K; Uhde M; Jorgensen L; Sobocki P; Johansson G
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa3927

Clinical and economic factors associated with spirometry-diagnosed COPD in the Swedish ARCTIC study

Johansson G; Larsson K; Stallberg B; Lisspers K; Olsson P; Gruenberger J-B; Jorgensen L; Sobocki P; Janson C
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa311

Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study

Roche N; Olsson P; Vestbo J; FowlerTaylor A; Ayers T; Thach C; Clerkin K; Fogel R; Patalano F; Banerji D
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa991

Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study

Wedzicha J; Chapman K; FowlerTaylor A; Ayers T; Thach C; Olsson P; Fogel R; Patalano F; Banerji D
Published conference paper: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2012;146(5):834-841

One Year after Endoscopic Sinus Surgery in Polyposis: Asthma, Olfaction, and Quality-of-Life Outcomes

Ehnhage A; Olsson P; Kolbeck K-G; Skedinger M; Stjarne P
Conference publication: ALLERGY. 2011;66:243

Swedish observational study on symptoms, treatment patterns, quality of life and costs in acute rhinosinusitis (SOSAR)

Stjarne P; Stallberg B; Odeback P; Lundberg J; Olsson P
Corrigendum: ALLERGY. 2010;65(3):412

Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. (vol 64, pg 1663, 2009)

Holmberg K; Tonnel A-B; Dreyfus I; Olsson P; Cougnard J; Mesbah K
Published conference paper: ARCHIVES OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY. 2009;135(3):296-302

Use of Mometasone Furoate to Prevent Polyp Relapse After Endoscopic Sinus Surgery

Stjaerne P; Olsson P; Alenius M
Thesis / dissertation: 2009

Prevalance of upper airway symptoms and aspects on treatment of nasal polyposis

Olsson, Petter
Letter: ACTA DERMATO-VENEREOLOGICA. 2009;89(3):305-307

A Randomized, Single-blind Comparison of the Efficacy, Tolerability and Cosmetic Acceptance of Propyless® or Fenuril® Treatment of Patients with Dry Skin

Faergemann J; Olsson P; Svensson A
Conference publication: ALLERGY. 2007;62:473-474

Efficacy of mometasone furoate nasal spray in the post-surgical treatment of nasal polyposis

Stjarne P; Olsson P
Visa fler

Anställningar

Anknuten till Forskning, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2023-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2009
Läkarexamen, Karolinska Institutet, 1993

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI